Document is current

Article History

Received: 7 October 2021

Accepted: 16 March 2022

First Online: 25 April 2022

Competing interests

: O.M. has received consultancy fees from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Ipsen, Lundbeck, Merck Sharpe & Dohme, Pfizer, Roche, Servier and Vifor Pharma, and has been an employee of Amgen since 1 February 2022. F.S. has received honoraria from Amgen, Biogaran, Bristol Myers Squibb, Helsinn, Leo Pharma, Merck Sharpe & Dohme, Mundi Pharma, Mylan, Pfizer, Pierre Fabre Oncology and Vifor Pharma. F.L. has been an employee of AstraZeneca France since 1 May 2019. E.B. has received honoraria from Novartis, Ipsen and Pfizer, research grants from Novartis, and is a member of Ipsen and Novartis speaker’s bureau. S.De. declares grants from F. Hoffmann-La Roche/Genentech during the conduct of the study and grants from Pfizer, Novartis, AstraZeneca, Lilly, Puma, Myriad, Orion, Amgen, Sanofi, Genomic Health, GE, Servier, Merck Sharp & Dohme and Bristol Myers Squibb outside of the submitted work; non-financial support from Pfizer, AstraZeneca and F. Hoffmann-La Roche/Genentech; and personal fees from AstraZeneca. D.Mal. declares competing interests with Agios, Amgen, Bayer, BMS, HalioDx, Incyte, Merck Serono, MSD, Pierre Fabre Oncologie, Roche, Sanofi, Servier and Shire. L.A. reports research funding from BMS (Institution) and advisory roles (Institution) for Astellas-AstraZeneca, BMS, Corvus Pharmaceuticals, Ipsen, Janssen, Merck & Co., MSD, Novartis, Pfizer and Eisai. P.P. has received consultancy fees from AstraZeneca, GSK and Clovis Oncology. C.R. has received consultancy fees from Amgen, Bristol Myers Squibb, Merck, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche and Sanofi. D.P. reports personal fees from AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, Prime Oncology, Peer CME, Roche and Samsung, outside the submitted work; and clinical trials research (as principal investigator or co-investigator): AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmune, Sanofi-Aventis, Taiho Pharma, Novocure and Daiichi Sankyo. S.d.B. has received research funding and served on an advisory board for Agios; participated in speakers’ bureaus and served on advisory boards for AbbVie, Bristol Myers Squibb and Janssen; served on an advisory board and provided consultancy to Pierre Fabre; and served on advisory boards for Astellas, Bayer, Daiichi‐Sankyo, Forma, Novartis, Pfizer, Servier and Syros. All other authors have no competing interests. The CAPRI academic system is owned by Gustave Roussy; none of the authors is involved financially with CAPRI. After this study, a commercial solution has been derived from CAPRI by RESILIENCE. None of the authors is involved financially with CAPRI or RESILIENCE.